TDO2 and cancer: Treatment of cancer cells in-vitro with IDO1-specific and/or TDO2 ASOs and small molecule inhibitors can reduce the production of KYN by cancer cells in a synergistic manner and increase proliferation of activated T cells in the co-culture [181].